This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Agoulnik, I. U. Articles by Weigel, N. L. Search for Related Content PubMed PubMed Citation Articles by Agoulnik, I. U. Articles by Weigel, N. L.

Androgens Modulate Expression of Transcription Intermediary Factor 2, an Androgen Receptor Coactivator whose Expression Level Correlates with Early Biochemical Recurrence in Prostate Cancer

Departments of ¹ Molecular and Cellular Biology, ² Pathology, and ³ Urology, Baylor College of Medicine; ⁴ Michael E. DeBakey Department of Veterans Affairs Medical Center, Houston, Texas

Requests for reprints: Nancy L. Weigel, Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Phone: 713-798-6234; Fax: 713-790-1275; E-mail: nweigel{at}bcm.edu.

Prostate cancer is an androgen-dependent disease; metastatic prostate cancer is typically treated by androgen receptor (AR) blockade. Recurrence after androgen ablation and evidence that AR continues to play a role in many prostate cancers has led to an examination of other factors that potentiate AR activity. AR is a ligand-activated transcription factor whose activity is regulated not only by hormone but also by the levels of coactivators recruited by AR to facilitate transcription. We sought to assess the consequences of reducing expression of the transcription intermediary factor 2 (TIF2) coactivator on prostate cancer cell growth and AR action in cell lines to examine TIF2 expression in prostate cancer and to correlate expression with clinical outcome. Depletion of TIF2 reduced expression of AR-induced target genes and slowed proliferation of AR-dependent and AR-independent prostate cancer cells. Remarkably, we found that TIF2 expression is directly repressed by high levels of androgens in multiple AR-expressing cell lines. Expression of a reporter containing 5'-flanking region of the TIF2 was repressed both by androgens and by the antagonist, Casodex. Expression of TIF2 correlates with biochemical (prostate-specific antigen) recurrence (P = 0.0136). In agreement with our in vitro findings, the highest expression of TIF2 was found in patients whose cancer relapsed after androgen ablation therapy, supporting the idea that AR blockade might activate pathways that lead to stimulation of AR-dependent and AR-independent proliferation of prostate epithelium. The elevated expression of TIF2 at low hormone levels likely aids in inducing AR activity under these conditions; treatment with Casodex has the potential to counteract this induction. (Cancer Res 2006; 66(21): 10594-602)

This article has been cited by other articles:

				M.-E. Taplin, M. M. Regan, Y.-J. Ko, G. J. Bubley, S. E. Duggan, L. Werner, T. M. Beer, C. W. Ryan, P. Mathew, S.-M. Tu, et al. Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer Clin. Cancer Res., November 15, 2009; 15(22): 7099 - 7105. [Abstract] [Full Text] [PDF]

				J. X. Zou, L. Guo, A. S. Revenko, C. G. Tepper, A. T. Gemo, H.-J. Kung, and H.-W. Chen Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer Cancer Res., April 15, 2009; 69(8): 3339 - 3346. [Abstract] [Full Text] [PDF]

				H. V. Heemers, K. M. Regan, L. J. Schmidt, S. K. Anderson, K. V. Ballman, and D. J. Tindall Androgen Modulation of Coregulator Expression in Prostate Cancer Cells Mol. Endocrinol., April 1, 2009; 23(4): 572 - 583. [Abstract] [Full Text] [PDF]

				S. Karmakar, E. A. Foster, and C. L. Smith Unique Roles of p160 Coactivators for Regulation of Breast Cancer Cell Proliferation and Estrogen Receptor-{alpha} Transcriptional Activity Endocrinology, April 1, 2009; 150(4): 1588 - 1596. [Abstract] [Full Text] [PDF]

				S. A Boorjian, H. V Heemers, I. Frank, S. A Farmer, L. J Schmidt, T. J Sebo, and D. J Tindall Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder Endocr. Relat. Cancer, March 1, 2009; 16(1): 123 - 137. [Abstract] [Full Text] [PDF]

				S. Feng, Q. Tang, M. Sun, J. Y. Chun, C. P. Evans, and A. C. Gao Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2 Mol. Cancer Ther., March 1, 2009; 8(3): 665 - 671. [Abstract] [Full Text] [PDF]

				I. U. Agoulnik, W. E. Bingman III, M. Nakka, W. Li, Q. Wang, X. S. Liu, M. Brown, and N. L. Weigel Target Gene-Specific Regulation of Androgen Receptor Activity by p42/p44 Mitogen-Activated Protein Kinase Mol. Endocrinol., November 1, 2008; 22(11): 2420 - 2432. [Abstract] [Full Text] [PDF]

				J. Yan, H. Erdem, R. Li, Y. Cai, G. Ayala, M. Ittmann, L.-y. Yu-Lee, S. Y. Tsai, and M.-J. Tsai Steroid Receptor Coactivator-3/AIB1 Promotes Cell Migration and Invasiveness through Focal Adhesion Turnover and Matrix Metalloproteinase Expression Cancer Res., July 1, 2008; 68(13): 5460 - 5468. [Abstract] [Full Text] [PDF]

				K.-i. Kozaki, I. Imoto, S. Mogi, K. Omura, and J. Inazawa Exploration of Tumor-Suppressive MicroRNAs Silenced by DNA Hypermethylation in Oral Cancer Cancer Res., April 1, 2008; 68(7): 2094 - 2105. [Abstract] [Full Text] [PDF]

				H. V. Heemers and D. J. Tindall Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex Endocr. Rev., December 1, 2007; 28(7): 778 - 808. [Abstract] [Full Text] [PDF]

				H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells Cancer Res., April 1, 2007; 67(7): 3422 - 3430. [Abstract] [Full Text] [PDF]